MORPHOLOGICAL AND MORPHOMETRIC ANALYSIS OF SEROTONIN-CONTAINING NEURONS IN PRIMARY DISSOCIATED CULTURES OF HUMAN RHOMBENCEPHALON - A STUDY OF DEVELOPMENT

Citation
C. Levallois et al., MORPHOLOGICAL AND MORPHOMETRIC ANALYSIS OF SEROTONIN-CONTAINING NEURONS IN PRIMARY DISSOCIATED CULTURES OF HUMAN RHOMBENCEPHALON - A STUDY OF DEVELOPMENT, Developmental brain research, 99(2), 1997, pp. 243-252
Citations number
25
Categorie Soggetti
Neurosciences
ISSN journal
01653806
Volume
99
Issue
2
Year of publication
1997
Pages
243 - 252
Database
ISI
SICI code
0165-3806(1997)99:2<243:MAMAOS>2.0.ZU;2-Q
Abstract
Primary dissociated cultures of rhombencephalon were prepared from 5-9 -week-old human fetuses. Half of some cultures were treated by two non -competitive N-methyl-D-aspartate antagonists, namely 1-(2-thienyl)cyc lohexylpiperidine (TCP) and /Mel-[1-(2-thienyl)-2-methyl-cyclohexyl]pi peridine (GK11) in negative enantiomeric form, which enhance the survi val of human fetal central nervous system cells in culture, At differe nt days in vitro, the treated and the control cultures were processed for immunocytochemical detection of serotonin-containing neurons which were studied by morphological and morphometric analysis. Statistical analysis showed that the surface of the stained neurons increased as a function of two parameters of time, the gestational age of the cells and the duration of the cultures. The complexity of the shape of the s erotonin neurons characterized by the shape factor, the number of bifu rcations and the morphological feature (bipolar or multipolar) was fou nd to increase with the gestational age. It appears that the in vitro development of the embryonic cells which represents stages of maturati on and differentiation can be specifically evaluated. Such an analysis of fetal central nervous system cells improves the knowledge of facto rs important in grafting experiments. We verified that the two drugs d o not appreciably alter the in vitro development of the treated cells; thus they may be considered as promising drugs for human neuroprotect ion. (C) 1997 Elsevier Science B.V.